AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25720848 — intervention group
Group type: EXPERIMENTAL
Intervention: Batroxobin
Number of subjects: 100
Study 25720848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23243239 — intervention group
Group type: EXPERIMENTAL
Intervention: BD supplemented with 0.5% HSCAS
Number of subjects: 100
Study 23243239 — intervention group
Group type: EXPERIMENTAL
Intervention: BD supplemented with 2.5 mg of AFB(1)/kg of feed and 0.5% HSCAS
Number of subjects: 100
Study 23243239 — intervention group
Group type: COMPARATOR
Intervention: BD supplemented with 2.5 mg of AFB(1)/kg of feed
Number of subjects: 100
Study 20628180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 250 mg given thrice weekly
Number of subjects: 99
Study 20628180 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 99
Study 19841338 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone for 2 weeks (monotherapy)
Number of subjects: 71
Study 19841338 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone for 2 weeks plus Ginkgo biloba for 4 weeks (combination therapy)
Number of subjects: 71
Study 19841338 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 71
Study 17075269 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily
Number of subjects: 0
Study 17075269 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release theophylline 5-8 mg/kg (dry syrup) or 100-200 mg (tablet) twice daily
Number of subjects: 0
Study 14657228 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy (arm B) - 70 Gy in 35 fractions with three cycles of a 4-day regimen comprising carboplatin and fluorouracil
Number of subjects: 226
Study 14657228 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (arm A) - 70 Gy in 35 fractions
Number of subjects: 226
Study 14657228 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy (arm B)
Number of subjects: 226
Study 14657228 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (arm A)
Number of subjects: 226
Study 11230586 — intervention group
Group type: COMPARATOR
Intervention: No cooling (rectal temperature = 37.0 +/- 0.2 degrees C, n = 15)
Number of subjects: 40
Study 11230586 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally cooled (rectal temperature 36.5 degrees C to 36 degrees C, n = 6)
Number of subjects: 40
Study 11230586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly cooled (rectal temperature 35.9 degrees C to 35.5 degrees C, n = 6)
Number of subjects: 40
Study 11230586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly cooled (rectal temperature 35 +/- 0.5 degrees C, n = 6)
Number of subjects: 40
Study 11230586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly cooled (rectal temperature 34.5 +/- 0.5 degrees C, n = 7)
Number of subjects: 40
Study 9880884 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of two endoloops with additional manual stump sinking
Number of subjects: 150
Study 9880884 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of endo-cutter
Number of subjects: 150
Study 9880884 — intervention group
Group type: COMPARATOR
Intervention: Application of two endoloops without stump sinking
Number of subjects: 150
Study 7977125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity anticoagulation (average INR 1.72)
Number of subjects: 75
Study 2535298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil, 5 micrograms/kg, IV with succinylcholine, 1 mg/kg, IV
Number of subjects: 20
Study 2535298 — intervention group
Group type: COMPARATOR
Intervention: Etomidate, 0.4 mg/kg, IV with succinylcholine, 1 mg/kg, IV
Number of subjects: 20
Study 1095310 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole therapy
Number of subjects: 202
Study 1095310 — intervention group
Group type: COMPARATOR
Intervention: Nystatin therapy
Number of subjects: 202
Study 30595354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (250 mg daily) plus MPH-ER (36 mg daily)
Number of subjects: 44
Study 30595354 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (250 mg daily) plus placebo
Number of subjects: 44
Study 29739386 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min games-based activity (basketball)
Number of subjects: 39
Study 26509366 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg/d during 7 days)
Number of subjects: 13
Study 26509366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 24561207 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUSEAL patching
Number of subjects: 200
Study 24561207 — intervention group
Group type: COMPARATOR
Intervention: Vascu-Guard patching
Number of subjects: 200
Study 23073950 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose multivitamin supplementation (daily oral supplements of vitamin B complex, vitamin C, and vitamin E at high levels)
Number of subjects: 3418
Study 23073950 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose multivitamin supplementation (daily oral supplements of vitamin B complex, vitamin C, and vitamin E at standard levels)
Number of subjects: 3418
Study 23073950 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose multivitamin supplementation
Number of subjects: 3418
Study 23073950 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose multivitamin supplementation
Number of subjects: 3418
Study 21708060 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 micrograms, once daily for 14 days
Number of subjects: 1141
Study 16675714 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 127
Study 16675714 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose testing (BGT)
Number of subjects: 127
Study 16675714 — intervention group
Group type: EXPERIMENTAL
Intervention: Family relationships
Number of subjects: 127
Study 15934992 — intervention group
Group type: EXPERIMENTAL
Intervention: IV magnesium (0.2 mg Mg per mL acid citrate dextrose‐A)
Number of subjects: 30
Study 15934992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12425542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 85
Study 12425542 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 85
Study 12425542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Lactobacillus spp. and bifidobacteria
Number of subjects: 85
Study 12425542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 10075273 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine in combination with zidovudine
Number of subjects: 89
Study 10075273 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with zidovudine
Number of subjects: 89
Study 9150972 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical hand‐transmitted repetitive shock vibration with exponential decays and hanning waveforms at 2.8 ms‐2 r.m.s. for various shock repetition rates (2 to 64 shocks per second)
Number of subjects: 0
Study 9150972 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock repetition rates of 2 to 64 shocks per second
Number of subjects: 0
Study 9150972 — intervention group
Group type: EXPERIMENTAL
Intervention: Current standards for assessing severity of hand‐transmitted vibration
Number of subjects: 0
Study 2024973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg) administered as a 1-h infusion
Number of subjects: 20
Study 2024973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg) administered as an oral tablet
Number of subjects: 20
Study 2024973 — intervention group
Group type: COMPARATOR
Intervention: Oral dosage form of ofloxacin
Number of subjects: 20
Study 7004771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T IUD
Number of subjects: 815
Study 7004771 — intervention group
Group type: COMPARATOR
Intervention: Copper-T-200 IUD
Number of subjects: 815
Study 7004771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IUDs
Number of subjects: 815
Study 6344900 — intervention group
Group type: EXPERIMENTAL
Intervention: M&B 22,948 (10 mg)
Number of subjects: 12
Study 6344900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29730707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanostructured carbonated hydroxyapatite (cHA) microspheres with BDGF
Number of subjects: 10
Study 29730707 — intervention group
Group type: COMPARATOR
Intervention: Nanostructured carbonated hydroxyapatite (cHA) microspheres alone
Number of subjects: 10
Study 30402473 — intervention group
Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA) 400 μg/kg.b.w
Number of subjects: 28
Study 30402473 — intervention group
Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA) 800 μg/kg.b.w
Number of subjects: 28
Study 30402473 — intervention group
Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA) 1600 μg/kg.b.w
Number of subjects: 28
Study 30402473 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 26823611 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.9% THC
Number of subjects: 18
Study 26823611 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.7% THC
Number of subjects: 18
Study 26823611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26823611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (approximately 0.065% peak breath alcohol concentration)
Number of subjects: 18
Study 24445087 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable radiation-absorbing surgical drapes
Number of subjects: 36
Study 22492127 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (IFNβ‐1b) 250 µg
Number of subjects: 0
Study 22492127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19747410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy product containing Lactobacillus casei DN-114001 (200 g/d)
Number of subjects: 1072
Study 17621025 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy without fusion (ACD)
Number of subjects: 42
Study 17621025 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy with intervertebral fusion (ACDF)
Number of subjects: 42
Study 17621025 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy with intervertebral fusion and instrumentation (ACDFI)
Number of subjects: 42
Study 16325660 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR clinical classification criteria
Number of subjects: 90
Study 16325660 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR clinical plus radiographic classification criteria
Number of subjects: 90
Study 16325660 — intervention group
Group type: COMPARATOR
Intervention: Rheumatoid arthritis (RA) control group
Number of subjects: 90
Study 12701728 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-channel CIS strategy (833 pps/channel, 75 micros/phase)
Number of subjects: 9
Study 12701728 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-channel CIS strategy (+/- 1,400 pps/channel, 21 micros/phase)
Number of subjects: 9
Study 12701728 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-channel CIS strategy (+/- 1,400 pps/channel, 21 micros/phase)
Number of subjects: 9
Study 10472396 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention including information on doping, discussions on nutritional supplements, drug simulating role play, and self-medication information.
Number of subjects: 476
Study 10472396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 476
Study 8598548 — intervention group
Group type: EXPERIMENTAL
Intervention: Kunitz trypsin inhibitor
Number of subjects: 6
Study 8598548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowman‐Birk inhibitor
Number of subjects: 6
Study 8598548 — intervention group
Group type: COMPARATOR
Intervention: Control (intraduodenal saline)
Number of subjects: 6
Study 1932482 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg cimetidine
Number of subjects: 9
Study 1932482 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine
Number of subjects: 9
Study 1932482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7140260 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 74
Study 7140260 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 74
Study 30651610 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine genomic sequencing of neonates
Number of subjects: 0
Study 30651610 — intervention group
Group type: COMPARATOR
Intervention: Standard newborn screening
Number of subjects: 0
Study 27852036 — intervention group
Group type: EXPERIMENTAL
Intervention: E39+250mcg GM-CSF (VG)
Number of subjects: 51
Study 27852036 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000mcg E39 (VG)
Number of subjects: 51
Study 26016936 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative Perfusion Solution (APS)
Number of subjects: 16
Study 26016936 — intervention group
Group type: COMPARATOR
Intervention: Steen group (SG)
Number of subjects: 16
Study 24039213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunglasses worn during daytime in addition to topical aqueous nasal budesonide and loratadine
Number of subjects: 39
Study 24039213 — intervention group
Group type: COMPARATOR
Intervention: Topical aqueous nasal budesonide and loratadine
Number of subjects: 39
Study 21507529 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthogeriatric Unit (OGU)
Number of subjects: 506
Study 17851462 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein hydrolysates (pea, rice, soy, gluten, whey, egg) with 0.2 g hydrolysate per kg body weight and 0.2 g maltodextrin per kg body weight
Number of subjects: 8
Study 17851462 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin alone
Number of subjects: 8
Study 17851462 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten protein hydrolysate
Number of subjects: 8
Study 17823625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 83
Study 17823625 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 83
Study 17823625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pioglitazone and atorvastatin
Number of subjects: 83
Study 17823625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 15064633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cineole (two 100‐mg capsules three times daily)
Number of subjects: 152
Study 15064633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 15064633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cineole
Number of subjects: 152
Study 12692603 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (E) at 800 mg/m²
Number of subjects: 10
Study 12692603 — intervention group
Group type: COMPARATOR
Intervention: Etoposide phosphate (EP) at 910 mg/m²
Number of subjects: 10
Study 10073771 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (n = 15)
Number of subjects: 30
Study 10073771 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit (n = 15)
Number of subjects: 30
Study 10073771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Heparin-coated and Uncoated circuits)
Number of subjects: 30
Study 8927524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightguide spectrophotometry measuring haemoglobin oxygenation (SO2)
Number of subjects: 41
Study 8927524 — intervention group
Group type: COMPARATOR
Intervention: Comparison with normal subjects (N=12)
Number of subjects: 41
Study 1911014 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 56 x 10(‐3) mol litre‐1
Number of subjects: 8
Study 1911014 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Intralipid
Number of subjects: 8
Study 1911014 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 8
Study 6785974 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphinpyrazone
Number of subjects: 186
Study 6785974 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 186
Study 31756730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 136
Study 31756730 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 136
Study 31221225 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine and conventional acupuncture
Number of subjects: 0
Study 31221225 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine and mind-regulating acupuncture
Number of subjects: 0
Study 31221225 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 0
Study 31221225 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 29746218 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming (carbon fiber resistive system - W-500D + 190 × 50 cm)
Number of subjects: 90
Study 29746218 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive warming (blanket, socks etc. for at least 20 minutes during preoperative period)
Number of subjects: 90
Study 29746218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active or passive warming)
Number of subjects: 90
Study 26932738 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day for 6 months)
Number of subjects: 159
Study 26932738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 24236828 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab (3.1 mg over 8 days)
Number of subjects: 54
Study 24236828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22300416 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparation (including a photo file, demonstration of equipment using a role-modelling approach, and a tour)
Number of subjects: 73
Study 22300416 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparation
Number of subjects: 73
Study 22300416 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control group with no specific preoperative education)
Number of subjects: 73
Study 20367660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of residual potentials as add-on therapy to circumferential pulmonary vein ablation (CPVA) + pulmonary vein electrical isolation (PVI), n = 49
Number of subjects: 102
Study 20367660 — intervention group
Group type: COMPARATOR
Intervention: No ablation of residual potentials, n = 53
Number of subjects: 102
Study 18670855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative gamma probe
Number of subjects: 32
Study 18670855 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy (LS)
Number of subjects: 32
Study 18670855 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue dye
Number of subjects: 32
Study 15932362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 10
Study 15932362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12559644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 12559644 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 0
Study 12559644 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 12559644 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam followed by Phenytoin
Number of subjects: 0
Study 10498160 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term diuretic therapy
Number of subjects: 34
Study 10498160 — intervention group
Group type: COMPARATOR
Intervention: No diuretic therapy (Control)
Number of subjects: 34
Study 8869791 — intervention group
Group type: EXPERIMENTAL
Intervention: AN-69 membrane
Number of subjects: 11
Study 8869791 — intervention group
Group type: COMPARATOR
Intervention: SPAN membrane
Number of subjects: 11
Study 1740212 — intervention group
Group type: EXPERIMENTAL
Intervention: CZB medium (supplemented with 0.11 mM ethylenediaminetetraacetic acid, 1.0 mM glutamine, 31.30 mM lactate, and 0.27 mM pyruvate)
Number of subjects: 49
Study 1740212 — intervention group
Group type: COMPARATOR
Intervention: EBSS medium (supplemented with 0.45 mM pyruvate)
Number of subjects: 49
Study 1740212 — intervention group
Group type: EXPERIMENTAL
Intervention: CZB medium
Number of subjects: 49
Study 1740212 — intervention group
Group type: COMPARATOR
Intervention: EBSS medium
Number of subjects: 49
Study 6238991 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 0
Study 6238991 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 6238991 — intervention group
Group type: COMPARATOR
Intervention: Independent of treatment
Number of subjects: 0
Study 30738562 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities (SHHC) program
Number of subjects: 101
Study 30738562 — intervention group
Group type: COMPARATOR
Intervention: Control group (93 women)
Number of subjects: 101
Study 30761790 — intervention group
Group type: EXPERIMENTAL
Intervention: NefraDoz (1 capsule three times daily for one month)
Number of subjects: 116
Study 30761790 — intervention group
Group type: COMPARATOR
Intervention: Standard antibacterial therapy (control group)
Number of subjects: 116
Study 26216648 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (6000 mg day(-1) of fish oil)
Number of subjects: 52
Study 26216648 — intervention group
Group type: COMPARATOR
Intervention: Control (6000 mg day(-1) of soybean oil)
Number of subjects: 52
Study 25135060 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g/kg/d)
Number of subjects: 15
Study 25135060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22571246 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Talk about Children intervention (2 meetings with parents)
Number of subjects: 19
Study 22571246 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (6 to 8 meetings with parents, children, and whole family)
Number of subjects: 19
Study 22571246 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GSI score of patients was at the same level as psychiatric outpatient sample; at 4-month follow-up, it was at the same level as in the general population.
Number of subjects: 19